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To provide a comprehensive overview of cardiovascular disease (CVD) risk prediction mod-
els for women and models that include female-specific predictors.
Methods
We performed a systematic review of CVD risk prediction models for women in the general
population by updating a previous review. We searched Medline and Embase up to July
2017 and included studies in which; (a) a new model was developed, (b) an existing model
was validated, or (c) a predictor was added to an existing model.
Results
A total of 285 prediction models for women have been developed, of these 160 (56%) were
female-specific models, in which a separate model was developed solely in women and 125
(44%) were sex-predictor models. Out of the 160 female-specific models, 2 (1.3%) included
one or more female-specific predictors (mostly reproductive risk factors). A total of 591 vali-
dations of sex-predictor or female-specific models were identified in 206 papers. Of these,
333 (56%) validations concerned nine models (five versions of Framingham, SCORE,
Pooled Cohort Equations and QRISK). The median and pooled C statistics were compara-
ble for sex-predictor and female-specific models. In 260 articles the added value of new
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predictors to an existing model was described, however in only 3 of these female-specific
predictors (reproductive risk factors) were added.
Conclusions
There is an abundance of models for women in the general population. Female-specific and
sex-predictor models have similar predictors and performance. Female-specific predictors
are rarely included. Further research is needed to assess the added value of female-specific
predictors to CVD models for women and provide physicians with a well-performing predic-
tion model for women.
Introduction
Differences between women and men in cardiovascular disease (CVD) have been recognized
decades ago [1], pertaining to clinical presentation, pathophysiological mechanisms, course of
disease and prognosis [2–6]. As symptoms of CVD are more subtle in women, there is often
delayed diagnosis, and thus treatment and consequently poorer prognosis and outcomes com-
pared with men [7]. It is crucial to identify sex differences to optimize diagnostic and manage-
ment strategies for both women and men [8]. Although women and men share many CVD
risk factors, which are often used in prediction models for the general population, there are
also female-specific risk factors. Well known examples are early menarche and menopause,
primary ovarian insufficiency, pregnancy complications, polycystic ovary syndrome, and use
of hormones [9–11].
Preventive measures are available to reduce the cardiovascular disease burden. Numerous
strategies to reduce the CVD burden have been implemented to identify persons at high risk.
As seen in a systematic review published in 2016, over 350 prediction models have been devel-
oped in recent years aiming to identify individuals at high CVD risk in the general population
[12]. Guidelines in Europe and the Unites States currently recommend the use of Systematic
COronary Risk Evaluation (SCORE) or the Pooled Cohort Equations in the general popula-
tion, both for women and men [13,14].
Although several female-specific CVD risk factors have been identified, predictors in most
implemented CVD prediction models seem generally similar for women and men. As clinical
presentation, pathophysiological mechanisms, course of disease and prognosis differ between
women and men; risk prediction likely differs between the sexes as well. Therefore, we aimed




For this review we used the results of the review by Damen et al on all future CVD prediction
models for the general population, both men and women [12]. As shown by this review, the
number of newly developed CVD prediction models grew excessively in recent years. For this
reason, we complemented the results of Damen et al, by performing an update of their search.
Details of the review by Damen et al were published previously [12]. In the original search,
Medline and Embase were searched until June 1st 2013 in order to identify articles on predic-
tion models for the occurrence of CVD in the general population, published after 2004.
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Articles which dated before 2004 were subtracted from the review by Beswick et al [15]. Arti-
cles were included when they reported one or more multivariable (i.e. including at least 2 pre-
dictors) prediction models, tools or scores to predict future CVD in the general population
(development papers), articles that investigated the added value of certain predictors (incre-
mental value papers) and articles that validated existing models (validation papers). Table 1
provides an overview of the key terminology.
For the present systematic review, we updated the search of Damen et al until 26th of July
2017. Title and abstract screening were conducted using the same in- and exclusion criteria as
Damen et al. However, in the full text screening we included only models specifically devel-
oped to predict CVD in women. We defined ‘model developed for women’ as 1) female-spe-
cific models, in which a separate model was developed in women only and 2) sex-predictor
models, in which sex was included as a predictor (e.g. covariate) in the model (Table 1). Mod-
els that were developed on men only or models that did not include sex as a predictor were
excluded. For the validation papers, only studies that validated a prediction model developed
for women were included. Studies in which a predictor was added to an existing model (incre-
mental value papers) were also included. Incremental value or validation studies in men only
were excluded.
Screening and data extraction
The titles and abstracts retrieved by the search were divided randomly among the researchers
(SJB, VD or LJJS) and screened independently. Studies were not screened in duplicate, but to
guarantee uniformity in screening, 30 abstracts were screened by all three researchers and dis-
cussed afterwards. In the screening stage, all papers that were labeled as ‘any doubt’ were
included for full text screening.
For full text screening the papers were divided in three different subsets for independent
screening by one of the three researchers (SJB, VD or LJJS). Again, full text screening was not
performed in duplicate, a subset of 20 papers from each researcher was screened by all three
researchers to achieve uniformity. Articles labeled as “any doubt” were resolved by discussion
among the three reviewers to reach consensus. Hand searching based on included articles and
’snowballing’ were used to search for additional studies.
Table 1. Key definitions.
Model developed for
women
A model developed for women, either separately for women (female-specific model) or
where sex is incorporated as a predictor (sex-predictor model)
Female-specific model A model developed in a dataset of women only, with a separate regression model or risk
chart for women
Sex-predictor model A model developed in a dataset of women and men, which uses sex as a predictor in the
model
Development When a new model is derived from a dataset
Incremental value paper When one or more predictors are added to an existing model to study whether the
performance of the model improves after adding the predictor(s)
Validation paper When the performance of an existing model is verified in a different population
Female-specific
predictor
A risk factor that is very clearly female specific such as: early menarche and menopause,
primary ovarian insufficiency, pregnancy complications, and polycystic ovary syndrome
Discrimination
C statistic
Indicates how well the model distinguishes between persons with an outcome event and
persons without an outcome event, often depicted as the C statistic
Measure of discrimination of the model and quantifies the area under the receiver
operator curve (ROC). Ranges from 0.5 to 1.0, where 0.5 resembles a coin-toss and 1.0 is
a perfect discrimination.
https://doi.org/10.1371/journal.pone.0210329.t001
Cardiovascular risk prediction models for women
PLOS ONE | https://doi.org/10.1371/journal.pone.0210329 January 8, 2019 3 / 14
Finally, data extraction was performed in a pre-specified data-extraction format based on
the CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction
Modelling Studies (CHARMS) [16]. All three reviewers read the papers and subsequently filled
in the data-extraction format together to guarantee agreement on the extracted information.
In this stage, disagreements were settled by an additional reviewer (JAAGD or YTvdS). For
papers in which a model was developed we extracted the same information as Damen et al.
and additionally determined whether the model was a female-specific or sex-predictor model.
All developed models were then assessed for quality based on reliability defined as 1) model
externally validated 2) model externally validated in a separate investigation/paper and 3) C
statistic> 0.7. If the development model did not report a C statistic, we used the mean C statis-
tic of the external validations. Reliable models, which met these criteria were assessed for clini-
cal usability for 1) 10 predictors or fewer, 2) full regression model or chart reported and 3)
availability of an online calculator.
For every included incremental value paper we extracted author, year, journal, the model
that was used to calculate incremental value and whether this model was female-specific or
sex-predictor and which predictors actually had incremental value. In addition, predictors
considered for incremental value were also extracted.
Finally, for the validation papers we extracted author, year, journal and which model was
validated. For the models that were validated >5 times and at least once in an external study,
we subsequently extracted additional information: characteristics of the validation cohort
(country, number of participants, age range, number of events), and performance measures
(Table 1). We also extracted whether the validation cohort existed of men and women or
women only (studies with men only were previously excluded). When studies used a cohort
consisting of both men and women, the model could be validated on men and women together
or separately. When validated in men and women separately we only included the validation
on women.
Descriptive analyses
Results are presented as counts or percentages where indicated. Combined summary measures
of studies and models (e.g. C statistics and number of participants in a cohort) are presented as
medians and/or ranges. Proportions were compared with the Chi-square test. C statistics of
the most frequently validated models were pooled with the R package metamisc [17]. We esti-
mated random-effect models using restricted maximum likelihood estimation, and derived
approximate 95% prediction intervals using the methods described in metamisc [17]. Analyses
were performed using SPSS 24 (IBM, Armonk, New York) or R (R Core Team, Vienna,
Austria).
Results
Fig 1 depicts the study flow diagram. From the study by Damen and colleagues, 249 articles
were included that described models developed for women. The updated search, after remov-
ing duplicates, resulted in 9348 new references. After title and abstract screening, 2290 articles
were eligible for full text assessment. Full text screening resulted in 244 included articles from
the updated search and two additional references identified through snowballing. These 246
papers were added to the 249 papers from Damen et al and in total, this review includes 495
papers on models for women (Fig 1).
In 133 papers prediction models for women were developed. In 206 papers a model was val-
idated and 260 papers concerned incremental value studies. Since papers can develop a model,
Cardiovascular risk prediction models for women
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validate a model and calculate the incremental value of a predictor on an existing model in the
same paper, these numbers do not add up to the total of 495 papers.
Development of new prediction models
In 133 distinct papers, 285 cardiovascular risk prediction models were developed. Of these,
160 (56%) were developed solely on women and are henceforth denoted as female-specific
models. The remaining 125 (44%) were sex-predictor models (Table 2). Table 2 shows the year
in which the models were published. Clearly, new models are still being developed in large
numbers, with the majority of the models developed in the last decade (on average 16 new
models developed each year). Before 1990, 62% of the developed models were sex-predictor
models. Between 1991 and 2010 female-specific models were developed more often than sex-
predictor models, since 2010 these proportions are equally divided.
Predictors in the development papers
For the models that were specifically developed for women, it was of particular interest
whether female-specific predictors were included in the model. Only 2 out of the 160 devel-
oped female-specific models (1.3%) included a female-specific risk factor. In the first,
Fig 1. Study flow diagram. The papers that were identified by the updated search were added to the papers from the
study by Damen and colleagues, resulting in a total of 495 papers.
https://doi.org/10.1371/journal.pone.0210329.g001
Table 2. Number of developed models over time.
Year 1967–1990 1991–2000 2001–2010 2011–2017 Total
Sex predictor 21 (62%) 21 (35%) 28 (35%) 55 (50%) 125 (44%)
Female specific 13 (38%) 39 (65%) 52 (65%) 56 (50%) 160 (56%)
Total 34 (100%) 60 (100%) 80 (100%) 111 (100%) 285 (100%)
https://doi.org/10.1371/journal.pone.0210329.t002
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D’Agostino and colleagues developed a model including menopause (yes/no) and an interac-
tion with menopause and age as predictors [18]. In the second, Parikh and colleagues consid-
ered the predictors pregnancy status, number of live births, age at menarche, menstrual
irregularity, age at first birth, stillbirths, miscarriages, infertility�1 year, infertility cause and
breastfeeding for inclusion in a model with established risk factors. The final model presented
included in addition to age the female-specific risk factors: menstrual irregularity, age at first
birth, still births, miscarriages and breastfeeding and had a C statistic of 0.675 in the derivation
cohort [19].
The median number of predictors for the female-specific models was 6 [IQR: 5–8] and for
the sex-predictor models was 8 [IQR: 7–10], including the predictor for sex. Fig 2 shows the
percentage of sex-predictor and female-specific models that included the nine most often-used
predictors. By definition sex was not a predictor in any of the female-specific models. Total
cholesterol was used more frequently in female-specific models (58% vs. 36%, difference 22%
95%CI 10%-33%). For the remaining eight predictors most frequently identified in the models
(age, smoking, diabetes mellitus, systolic blood pressure, HDL, hypertension, diastolic blood
pressure, and LDL), the frequency of predictors used was similar for the both model types.
The apparent C statistic (i.e. the C statistic in the development models) was reported in 66
(53%) of the sex-predictor models and in 59 (37%) of the female-specific models. The median
of the C statistics were similar (0.797 for the sex-predictor models [range: 0.610–1.000] and
0.787 for the female-specific models [range: 0.660–0.918]). The full list of identified develop-
ment papers in the updated search is available as S1 Table.
Validation of prediction models
A total of 206 articles described 591 validations of sex-predictor or female-specific models. The
models that were validated more than five times and at least once in a separate paper, were;
SCORE Conroy 2003 (n = 63), Framingham Wilson 1998 (n = 61 validations), Pooled Cohort
Equations Goff 2013 (n = 52), Framingham D’Agostino 2008 (n = 48), Framingham Anderson
1991a (n = 40), Framingham ATP III 2002 (n = 29), Framingham Wolf 1991 (n = 20), Fra-
mingham Anderson 1991b (n = 14), and QRISK Hippisley-Cox 2007 (n = 6) (Table 3). The
333 validations of these nine models will be discussed further. The only model that is a sex-pre-
dictor model is Framingham Anderson 1991a, which was validated 15 (37%) times in men and
Fig 2. Most frequently used predictors for the sex predictor and female-specific models. HDL; High-density
lipoprotein. Total Chol; total cholesterol. LDL; Low-density lipoprotein. SBP; systolic blood pressure. DBP; Diastolic
blood pressure.
https://doi.org/10.1371/journal.pone.0210329.g002
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women and 25 (63%) times in women only. The eight female-specific models were validated
119 (41%) times in men and women together. The other 174 validations (59%) were performed
in women only. A C statistic was reported in 70% of these validation studies and ranged from
0.449 to 0.993. Pooled C statistics showed similar performances in validations performed on
women only and validations on men and women together (Table 4). The full list of validated
models identified in the updated search is available as S2 Table.
Incremental value
In 260 articles the added value of a predictor to an existing female-specific or sex-predictor
model was described. In 3 (1.1%) papers female-specific risk factors were added to an existing
model, all of which were recently published (2016 n = 2 and 2017 n = 1) [20–22]. In the previ-
ously discussed paper by Parikh and colleagues, female-specific predictors were added to
established risk factors, resulting in a final model including age at first birth, still births, mis-
carriages and breastfeeding. This slightly improved the model, C statistic of 0.730, where the
model with only established risk factors had a C statistic of 0.726 [19]. In a study by van der
Meer and colleagues, the female-specific predictors age at menarche, menopausal status/age,
hormone use, gestational hypertension and diabetes, number of children, miscarriages/still-
births were added to established risk factors. The addition of these predictors did non appar-
ently improve the discrimination or calibration of the model beyond the established risk
factors [23]. In the third paper, Zhou and colleagues added amongst other predictors (African
American ethnicity, physical exercise level, BMI, waist circumference, height, HDL choles-
terol), use of hormone replacement therapy in postmenopausal women to the Framingham
Table 3. Characteristics of the validations of the nine most frequently validated prediction models.
1 2 3 4 5 6 7 8 9
SCORE Framingham Pooled Cohort
Equations
Framingham Framingham Framingham Framingham Framingham QRISK
Conroy
2003
Wilson 1998 Goff 2013 D’Agostino
2008
Anderson 1991 ATP III 2002 Wolf 1991 Anderson 1991 Hippisley-Cox
2007
n = 63 n = 61 n = 52 n = 48 n = 40 n = 29 n = 20 n = 14 n = 6
Composition of validation cohorts
Men and
Women
26 27 16 28 15 15 6 1 0
Women
Separately
37 34 36 20 25 14 14 13 6
Location of the validation cohorts
Asia 8 7 8 10 1 1 1 1 0
Australia 4 0 1 1 10 1 0 1 0
Europe 43 20 7 22 28 3 9 8 6
North America 8 32 34 13 1 24 10 4 0
Participant age in the validation cohorts
Min, median 40 40 40 40 35 45 55 35 35
Max, median 65 74 79 79 74 82 99 64 74


























213 [8–24659] 150 [9–4658] 146 [15–
18173]
86 [1–29057] 384 [35–2343] 160 [24–939] 158 [5–18173] 29057 [18027–
29057]
https://doi.org/10.1371/journal.pone.0210329.t003
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Stroke Risk Score (Wolf 1991). The addition of this predictor set improved discrimination and
calibration of the model in women; however, the separate performance of hormone use was
not reported [24]. The full list of incremental value papers identified by the updated search is
available as S3 Table.
Reliability and clinical usability of available models
All 285 models developed for women were first assessed for reliability and were regarded so if
they met the following criteria: 1) model externally validated 2) externally validated in a sepa-
rate investigation/paper and 3) a C statistic >0.7. Of the 285 models, 40 (14%) met these crite-
ria and were considered reliable (Table 5). Of these 40, 25 (63%) were female-specific and 15
(37%) were sex-predictor models. Following, these models were assessed for clinical usability
based on the presence of 1) 10 predictors or fewer, 2) full regression model or chart reported
and 3) online calculator available (Table 5). The SCORE and Framingham 2008 model had the
highest usability score as they met all criteria. Other models with high usability are the Pooled
Cohort Equations (African American), Framingham 30 year and the Framingham stroke mod-
els as they have 10 or fewer predictors and an online calculator available. The remaining mod-
els either had more than 10 predictors or no calculator available, rendering them less
appealing for clinical practice.
Discussion
In this study we provided an overview of the available CVD risk assessment models for women
in the general population. We identified a wide range of models that have been developed over
the past decades, including 160 female-specific models (i.e. models that are developed for use
in women only) and 125 sex-predictor models (i.e. models that include sex as a predictor).
Despite this large quantity, only two of the 160 (1.3%) female-specific models included female-
specific predictors [18,19]. Of the 260 studies in which the added value of a predictor was
assessed, only three (1.1%) investigated the added value of a female-specific predictor
[19,23,24].
Table 4. Pooled C statistics of the validations of the nine most frequently validated prediction models.
1 2 3 4 5 6 7 8 9
SCORE Framingham Pooled Cohort
Equations
Framingham Framingham Framingham Framingham Framingham QRISK
Conroy
2003








Validations on men and women
n = 15 n = 17 n = 9 n = 21 n = 8 n = 11 n = 3 n = 0 n = 0







(0.679–0.799) (0.600–0.868) —a (0.593–0.846) —a — —
Validations on women separately
n = 13 n = 18 n = 28 n = 10 n = 13 n = 8 n = 8 n = 2 n = 3







(0.696–0.819) (0.544–0.916) (0.755–0.796) (0.568–0.806) (0.447–
0.908)
—b (0.750–0.843)
a Due to limited information the resulting prediction interval lies outside the possible interval (values >1 and/or <0)
b Not enough validations were available to calculate the prediction interval
https://doi.org/10.1371/journal.pone.0210329.t004
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Our study has several major strengths. We performed an extensive search up to July 2017
and systematically selected studies for inclusion. Detailed and thorough data extraction of
essential information such as type of models, predictors, population and model discrimination,
was performed by means of standardized forms and was done by three investigators together
for the development models to ensure uniformity. Limitations of our study should be men-
tioned. First, we did not include models specifically made for men and thus could not compare
differences in performance and predictors between men and women. Second, in some valida-
tion studies it was not clear which models were validated when the original development arti-
cle reported on more than one model. We assumed that all models in the article were
validated, but this may have led to an overestimation of the actual number of times prediction
models were validated. Third, we did not include articles written in a language different than
English and articles of which the full text could not be retrieved. Furthermore, validation
papers were excluded from the pooled C statistic analyses when insufficient information neces-
sary for pooling was reported. In addition, since we did not conduct a formal risk of bias
assessment, we were only able to include all validation studies in which reporting was com-
plete, instead of including for example studies with the smallest risk of bias. Therefore, results
on the pooled C statistics, should be interpreted with caution. Finally, as calibration was
reported in a heterogeneous manner, conclusions for this performance measure could not be
drawn. Furthermore, in papers the measure for calibration was often not reported. In order to
guarantee uniformity, new studies reporting on prediction models should adhere to the
Table 5. Clinical usability of models that met the reliability criteria.
Model–study name Author—Year Number of separate
models




Framingham Anderson 1991a 12 ✓ ✓ ✕ ✕
Framingham Anderson 1991b 2 ✓ ✓ ✓ ✕
— Assmann 2007 2 ✓ ✕ ✓ ✕
ARIC Chambless 2003 2 ✕ ✓ ✕ ✓
SCORE Conroy 2003 6 ✓ ✓ ✓ ✓
Framingham D’Agostino 2008 2 ✓ ✓ ✓ ✓
Framingham ATP II 1 ✓ ✓ ✓ ✕
— Gaziano 2008 2 ✓ ✕ ✓ ✕
Pooled Cohort Equations (African
American)
Goff 2013 1 ✓ ✓ ✕ ✓
Pooled Cohort Equations
(White)
Goff 2013 1 ✕ ✓ ✕ ✓
QRISK Hippisley-Cox
2007
1 ✓ ✕ ✕ ✕
QRISK2 Hippisley-Cox
2008
2 ✕ ✕ ✕ ✕
QRISK lifetime Hippisley-Cox
2010
1 ✕ ✕ ✕ ✓
— Lumley 2002 1 ✓ ✕ ✓ ✕
Framingham (30 yrs) Pencina 2009 1 ✓ ✕ ✕ ✓
— Schnabel 2009 1 ✓ ✕ ✓ ✕
Framingham Wilson 1998 1 ✓ ✓ ✓ ✕
Framingham (Stroke) Wolf 1991 1 ✓ ✕ ✓ ✓
Clinical usability was scored for the models which met all criteria for reliability: 1) model externally validated 2) externally validated in a separate investigation/paper
and 3) a C statistic >0.7.
https://doi.org/10.1371/journal.pone.0210329.t005
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Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diag-
nosis (TRIPOD) statement [25,26].
The models described in this review often comprise several variations of established, sex-
independent predictors such as age, blood pressure, lipid levels and smoking indicating that
these predictors attribute most to the current performance of the models. Interestingly, the
results showed that both the female-specific models as well as the sex-predictor models often
comprise these same established predictors and do not differ substantially in estimated C sta-
tistic. This might imply that using sex as predictor in a model is just as effective as developing a
female-specific model. Of the nine most frequently validated models in women the C statistic
as a measure of performance was reported in 59% of the validation studies. Pooled C statistics
indicated good performance in general (pooled C statistic >0.70 for most models), although
the range of reported C statistics varied from 0.45 to 0.99. This indicates that although these
models generally perform well, they can definitely be improved. Of all 285 developed models,
only 40 (14%) met the quality criteria for reliability. When these models were further assessed
for clinical usability only 2/40 (5%), the SCORE and Framingham 2008 model, met all criteria.
Other models which met most criteria and had a risk calculator available were the Pooled
cohort equations, Framingham 30 years and Framingham stroke model. Based on both these
reliability and clinical usability criteria, these models seem best suitable for implementation in
clinical practice. Models without an online calculator are likely less attractive for use in clinical
practice.
Our findings are in line with a previous study by Goh and colleagues, in which the utility of
CVD prediction models for women was appraised [20]. They also concluded that there is
room for improvement in CVD prediction models for women and this could be achieved by
adding predictors which may perform well in women. Remarkable is that none of the predic-
tors suggested by Goh, such as obesity, physical activity and coronary artery calcium, are
female-specific. It must be noted that in the study by Goh and colleagues the search was lim-
ited to five years before publication (2008–2013). The study was restricted to six models, where
we in our study considered any model identified by the search strategy. The 2011 guidelines
for the prevention of CVD in women [27] categorize women as ‘at risk’ when having one or
more major risk factors. Aside from the established risk factors found in most prediction mod-
els, they explicitly include the female-specific risk factors of a history of preeclampsia, gesta-
tional diabetes, or pregnancy-induced hypertension. However, none of these disorders are
used in any of the prediction models for women in this review.
Although many models have been developed in women only, it seems that differences
between men and women in CVD risk assessment are still not fully recognized. Many female
specific risk factors for CVD have been identified in recent years, but their predictive potential
has not been tested or even considered in risk prediction models within the scope of our
review. Our search only identified two development studies that included a female-specific
predictor in the model [18,19]. Improvement of the existing models might be achieved in add-
ing female-specific predictors. However, in most of the incremental value studies we found,
female-specific predictors were not even considered as potential predictors for added value. Of
the 260 incremental value studies, three added a female-specific predictor. Of these, one
reported no improvement in performance and one observed a slight improvement in discrimi-
nation. The third did not report on improvement of individual predictors. A reason for not
finding any substantial improvement could be that studies missed information on several
important female-specific risk factors like preeclampsia, polycystic ovary syndrome and infant
birth weight. Therefore, it is important to further investigate the potential added value of
female-specific predictors. Most female-specific predictors become apparent at an early stage
in life whereas CVD events mostly occur after the age of 50. An additional benefit is that these
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predictors can be easily obtained from the medical history. This underlines the potential of
these predictors, as risk assessment is ideally performed decades before the anticipated event,
in order to implement and optimize effect of preventive strategies. Although we identified a
total of 495 papers on CVD prediction models for women, it is still uncertain whether these
can be improved by female-specific predictors. However, it should be mentioned that finding
new predictors that improve model performance on top of the well-known predictors seems
challenging [22]. It is possible that current models, which often aim to estimate the 10-year
risk based on a single assessment, have reached their maximal predictive potential and cannot
be further improved. A new type of model, for example the dynamic model, in which an indi-
vidual’s risk is continuously updated over time, could further advance preventive strategies.
Conclusions
In conclusion, there is an abundance of models for women in the general population, but
female-specific predictors are rarely included. The few studies that add female-specific risk fac-
tors to existing CVD risk models do not show substantial improved performance, but lacked
important potential predictors. Further research in order to provide physicians with a well-
performing and properly validated prediction model for women is therefore warranted, con-
sidering all female-specific predictors. Ideally their added value to models which already per-
form well is assessed instead of developing completely new models [12].
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